Imagine a world where doctors are able to target and remove pathogens, such as harmful cells, bacteria, toxins, and inflammatory cytokines, directly from a patient’s bloodstream. The ability to precisely extract unwanted disease causing substances in this way would revolutionise the treatment of deadly blood-borne diseases, benefiting patients and clinicians around the world. That is MediSieve’s vision for the future of healthcare, and it can be achieved through the process of magnetic blood filtration.
MediSieve’s first product targets IL-6 cytokine to treat various hyperinflammation condition like Sepsis, COVID-19, and Cytokine Release Syndrome.
MediSieve plans to use a combination of different magnetic beads to target the various pathogens and cytokines that lead to the symptoms of Sepsis.
The device rapidly reduces the parasitaemia of severe Malaria patients who have been hospitalised and prescribed IV drug treatment.
The MediSieve System purifies blood by targeting harmful substances with magnetic beads
Oregon Translational Research and Development Institute
Virtual, 8-10th September 2021
Brussels, 31st August-3d September 2021
MediSieve Ltd, a biotech company which has developed an innovative blood filtration device, today a...